Medicis Closes License Of ORAPRED To BioMarin With Option To Purchase

Medicis (NYSE:MRX) today announced it has closed its previously announced asset purchase agreement and license agreement, and signed a securities purchase agreement with BioMarin Pharmaceutical Inc. (“BioMarin”) (Nasdaq and SWX: BMRN).

MORE ON THIS TOPIC